Effient, known generically as prasugrel, is a medication prescribed to reduce the risk of thrombotic cardiovascular events, such as heart attack and stroke, in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI) [1]. It is administered as a 10 mg tablet [1].
How does Effient work?
Effient is an antiplatelet medication that works by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on platelets [2]. This inhibition prevents ADP from binding to the receptor and activating platelets, thereby reducing platelet aggregation and thrombus formation [2].
What is Effient used for?
Effient is used in adult patients with ACS who are scheduled for PCI to prevent blood clots [1]. It is typically prescribed along with aspirin [1].
What are the side effects of Effient?
Common side effects of Effient include bleeding, bruising, and dyspnea [3]. More serious risks include severe or life-threatening bleeding [3]. Patients should report any unusual bruising, bleeding, or signs of bleeding to their doctor immediately [3].
When does Effient's patent expire?
The patent protection for Effient has largely expired, allowing for the potential development and marketing of generic versions [4]. Information on specific patent expiration dates can be found on resources like DrugPatentWatch.com [4].
Can generic versions of Effient be produced?
With the expiration of key patents, generic versions of prasugrel, the active ingredient in Effient, can be manufactured and marketed [4]. This often leads to increased accessibility and potentially lower costs for patients [4].
How does Effient compare to other antiplatelet medications?
Effient is a P2Y12 inhibitor, similar to clopidogrel (Plavix) and ticagrelor (Brilinta). While all work to prevent platelet aggregation, they have differences in their mechanisms of action, potency, and side effect profiles [5]. Clinical trials have compared these agents, with Effient demonstrating potent antiplatelet activity [5].
What are the risks associated with stopping Effient?
Stopping Effient prematurely can increase the risk of thrombotic events, including heart attack and stroke, particularly in patients who have undergone PCI [1]. Patients should consult their healthcare provider before discontinuing the medication [1].
Who makes Effient?
Effient was originally developed by Daiichi Sankyo and Eli Lilly and Company [6]. Generic versions are produced by various pharmaceutical manufacturers.
What is the typical dosage of Effient?
The standard maintenance dose for Effient is 10 mg once daily, taken with or without food [1]. For patients with ACS who weigh less than 60 kg, a lower dose may be prescribed [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/effient
[2] https://www.drugpatentwatch.com/drugs/prasugrel
[3] https://www.drugpatentwatch.com/drugs/effient/side-effects
[4] https://www.drugpatentwatch.com/drugs/effient/patent-status
[5] https://www.drugpatentwatch.com/drugs/ticagrelor
[6] https://www.drugpatentwatch.com/drugs/effient/manufacturer